Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2026-09-03 18:55:11 ET · period of report 2026-09-01 · accession 0001193125-26-382245 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-03 18:55 | 2026-09-01 | FDMT | Bizily Scott | CLO | M - OptEx | $6.49 | +584 | 9,201 | +7% | +$3,790 |
| DT | 2026-09-03 18:55 | 2026-09-01 | FDMT | Bizily Scott | CLO | S - Sale+OE | $14.00 | -584 | 8,617 | -6% | -$8,176 |
| DT | 2026-09-03 18:55 | 2026-09-01 | FDMT | Bizily Scott | CLO | M - OptEx | $0.00 | -584 | 2,959 | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-01 | M | A | 584 | $6.49 | 9,201 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. |
| 2 | Common | Common Stock | 2026-09-01 | S | D | 584 | $14.00 | 8,617 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-09-01 | M | D | 584 | $0.00 | 2,959 | D | $6.49 · — to 2032-06-17 | 584 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. (F2) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |